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Abstract
Background: Fermentation is a widely used method of natural food preservation that has consequences on the nutri-
tional value of the transformed food. Fermented dairy products are increasingly investigated in view of their ability to
exert health benefits beyond their nutritional qualities.
Objective: To explore the mechanisms underpinning the health benefits of fermented dairy intake, the present study
followed the effects of milk fermentation, from changes in the product metabolome to consequences on the human
serum metabolome after its ingestion.
Methods: A randomized crossover study design was conducted in 14 healthy men [mean age: 24.6 y; mean body mass
index (in kg/m2): 21.8]. At the beginning of each test phase, serum samples were taken 6 h postprandially after the
ingestion of 800 g of a nonfermented milk or a probiotic yogurt. During the 2-wk test phases, subjects consumed 400 g
of the assigned test product daily (200 g, 2 times/d). Serum samples were taken from fasting participants at the end of
each test phase. The serum metabolome was assessed through the use of LC-MS–based untargeted metabolomics.
Results: Postprandial serum metabolomes after milk or yogurt intake could be differentiated [orthogonal projections to
latent structures discriminant analysis (OPLS-DA) Q2 = 0.74]. Yogurt intake was characterized by higher concentrations
of 7 free amino acids (including proline, P = 0.03), reduced concentrations of 5 bile acids (including glycocholic acid,
P = 0.04), and modulation of 4 indole derivative compounds (including indole lactic acid, P = 0.01). Fasting serum
samples after 2 wk of daily intake of milk or yogurt could also be differentiated based on their metabolic profiles (OPLS-
DA Q2 = 0.56) and were discussed in light of the postprandial results.
Conclusions: Metabolic pathways related to amino acids, indole derivatives, and bile acids were modulated in healthy
men by the intake of yogurt. Further investigation to explore novel health effects of fermented dairy products iswarranted.
This trial was registered at clinicaltrials.gov as NCT02230345. J Nutr 2018;148:851–860.
Keywords: metabolomics, dairy, yogurt, milk, postprandial, indole derivatives, bile acids, fermentation, gluconic
acid, healthy men
Introduction
Fermentation of milk was first used by cattle herders as a
way to extend storage life, facilitate transportability, and,
by reducing lactose content, improve digestibility (1). Today,
∼20–40 kg of fermented dairy products are consumed per per-
son each year in Western countries, of which ∼40% is repre-
sented by yogurt (2, 3). During fermentation, the proteolytic
and lipolytic activities of lactic acid bacteria (LAB), as well as
the conversion of milk carbohydrates to alcohols, carbon diox-
ide, and organic acids, cause major changes in the product’s
final composition and organoleptic properties. Consequently,
these foods have been extensively evaluated for their role in
health. In particular, the beneficial effects of yogurt have been
investigated for more than a century (4) and include immune
function modulation, lowering of circulating cholesterol, and
improvements in a range of gastrointestinal conditions such
as lactose intolerance, constipation, diarrheal diseases, colon
cancer, inflammatory bowel disease, Helicobacter pylori infec-
tion, and allergies (5–7). However, the mechanisms underpin-
ning these potential properties are not yet well-established,
although many compounds that result from the bioactivity of
LAB have been associated with the reported health benefits of
yogurt, such as conjugated linoleic acid (8), sphingolipids (9),
or bioactive peptides (10, 11). Moreover, the health qualities of
yogurt may rely not only on the production of bioactive metabo-
lites during milk fermentation, but also on both the activity of
the LAB in the gut and the modulation of the host intestinal
microbiota (12).
The use of untargeted metabolomics in dietary interventions
is a promising approach as the method can give a snapshot
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of the metabolic activity of a subject at a specific time point
after the ingestion of a test food (13–15). However, to date, few
nutritional intervention studies investigating fermented dairy in-
take have used metabolomics (16–21). The primary aim of the
present study is to evaluate the metabolic response of healthy
men to the ingestion of a fermented dairy product with the use
of an untargeted metabolomics approach. The impact of fer-
mentation on the milk metabolome is investigated, as is that of
fermented milk ingestion on the serum metabolome, both post-
prandially and fasting after short-term daily intake.
Methods
Subjects. The subjects were healthy adult men (n = 14) aged
24.6 ± 4.7 y (mean ± SD) and with a BMI (in kg/m2) of 21.8 ± 1.8
(mean ± SD) (Supplemental Table 1). None of the subjects had evi-
dence of intolerance or adverse reactions to dairy products. Details re-
garding exclusion criteria and the inclusion visit are given by Burton
et al. (22). One subject was excluded from all analyses due to suspected
noncompliance with dietary instructions that was detected during mi-
crobiota analysis (22). Another subject withdrew before completing the
final test day due to acute illness (Supplemental Figure 1). Before en-
tering the study, all subjects provided written informed consent. The
study was conducted in accordance with the Declaration of Helsinki
as revised in 1983 and received ethical approval from the Commission
Cantonale d’Ethique de la Recherche sur l’Etre Humain (CER-VD, ap-
proval number 392/13, Vaud, Switzerland). The study was registered at
clinicaltrials.gov as NCT02230345.
Test products. The fermented test product was a yogurt produced by
fermentation ofmilk with classical yogurt starter cultures and thewidely
used probiotic Lactobacillus rhamnosus Gorbach-Goldin (LGG) (23).
Starter cultures consisted of a mix of Lactobacillus delbrueckii ssp. bul-
garicus and Streptococcus thermophilus and were obtained from Chr.
Hansen A/S, Denmark (Thermophilic Yoflex). The probiotic LGG was
obtained from the Culture Collection of the University of Goteborg,
Sweden (CCUG 34,291). The nonfermented dairy control was a chem-
ically acidified milk obtained by the addition of 2% glucono-δ-lactone
(GDL, ≥99.0%, Jungbunzlauer AG, Switzerland). The addition of 2%
GDL to milk mimics the slow pH reduction occurring during fermen-
tation and allows the final product to have a color, texture, and pH
similar to a mild semiliquid yogurt. All the milk used in the study was
provided by Emmi (MittellandMolkerei AG, Switzerland) from a single
production batch. Details of product preparation, nutritional composi-
tion, and biochemical analyses are given in the Supplemental Methods
and Supplemental Table 2.
Study design. The intervention study used a randomized, double-
blind, and crossover design (Figure 1). The postprandial response to the
acute intake of milk or yogurt was assessed at the beginning of each
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intervention phase. During this test day, participants ingested a single
800-g dose of milk or yogurt within 15 min and serum was sampled
postprandially up to 6 h (fasting, then 15, 30, 60, 90, 120, 180, 240,
300, and 360 min). The dose of 800 g, although uncommon in nor-
mal dietary situations, was chosen to amplify the postprandial effect of
dairy intake, thereby facilitating the identification of themetabolites and
metabolic pathways that are most likely to change after normal chronic
intake. Such an acute approach has been previously used to character-
ize postprandial lipidemia after dairy intake (24) or to identify post-
prandial biomarkers of dairy intake (25). During the following 2 wk,
subjects were instructed to consume 400 g of the assigned test product
daily (200 g morning and evening) and fasting serum was taken at the
end of the 2-wk period to evaluate the effect of short-term intake on the
fasting serum metabolome. During the 3-wk run-in and 2-wk washout
periods, participants consumed 400 g of nonacidified (normal) milk per
day (200 g morning and evening). Dietary intake was semicontrolled
during all phases of the study with specific guidance given on portions
of fermented foods, alcohol intake, and coffee intake. Participants were
instructed to exclude all dairy products from their diet except those pro-
vided. Before each test day, participants followed a 3-d controlled diet
by only consuming food provided by the investigators (22).
Untargeted metabolomics. Serum and products samples were
kept at −80°C before being analyzed with the use of the same pro-
tocol. To limit ion-suppression, phospholipids were removed from the
samples by the Phree filter (Phenomenex Inc., Torrance, CA). An ultra-
high-pressure LC system, coupled to a quadrupole time-of-flight mass
spectrometer, was applied for untargeted metabolomics analysis (Ulti-
Mate 3000,Thermo Fisher Scientific,Waltham,MA, coupled to amaXis
4G+, Bruker Daltonik GmbH, Bremen, Germany). The mass spectrom-
eter electrospray interface was operating in positive ion mode and spec-
tra were recorded fromm/z 75 tom/z 1500. In light of the large number
of samples to be measured and the better coverage of the metabolome in
the positive mode (26), positive mode was favored over negative mode.
Details regarding sample preparation and LC-MS protocol are given in
the Supplemental Methods.Mass-spectrometer signal drift was assessed
with the regular injection of a quality control sample (QC) consisting
of either a pool of all serum samples or all products samples. Contam-
inants were accounted for by the injection of a blank (ultrafiltered wa-
ter). For metabolite identification, the Human Metabolome Database
(27), the MassBank of North America (28), the National Institute of
Standards and Technology database (NIST v14), and Metlin (29) were
used with a 5 ppm accuracy threshold. Identities of selected metabo-
lites were confirmed by performing collision-induced dissociation (5–70
eV collision energies) and/or with the injection of standards. Standards
were either purchased separately or obtained from the Mass Spectrom-
etry Metabolite Library kit (MSMLS, IROA Technologies, LLC, Bolton,
MA; Gainesville, FL). If absent from the MSMLS kit, bile acid (BA)
identities were confirmed with the injection of a bile salt extract solu-
tion. All solvent, reagents, and standards were purchased from Sigma-
Aldrich Chemie GmbH (Buchs, Switzerland). As the analysis is semi-
quantitative, the concentrations mentioned in the text refer to relative
concentrations, determined from the metabolites’ peak area (arbitrary
unit).
Data processing and statistical analysis. Progenesis QI
(v.2.3.6198.24128, NonLinear Dynamics Ltd., Newcastle upon Tyne,
United Kingdom) was used for retention time correction, peak-picking,
deconvolution, and normalization with default settings (default auto-
matic sensitivity and without minimum peak width). Signal drift cor-
rection was performed with R (v.3.1.2; R Foundation for Statistical
Computing, Vienna, Austria) via the QC-based robust locally estimated
scatterplot smoothing signal correction method (30). Metabolites with
poor repeatability, i.e., detected in <50% of QCs and with a relative
standard deviation (RSD) >30% in the QC samples, were removed.
Also, features that had a median in the QC samples that was <3 times
higher than the median calculated for the blanks were excluded. For
each metabolite, nonparametric analysis of longitudinal data (nparLD)
was performed to test the hypothesis that a time effect exists post-
prandially (nparLD R package, 0.05 as P significance cutoff) (31).
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FIGURE 1 Overview of study design. Participants were assigned randomly to group 1 or group 2 in a crossover design to test the acute
and short-term intake of acidified milk and yogurt. At the beginning of each test phase, serum samples were taken 6 h postprandially after the
ingestion of 800 g of a nonfermented milk or a probiotic yogurt. During the 2-wk test phases, subjects consumed 400 g of the assigned test
product daily (200 g, 2 times/d). Serum samples were taken from fasting participants at the end of each test phase. A washout period separated
each test phase and a run-in preceded the beginning of the study. Subjects consumed 400 g of regular milk/d during the run-in and washout
periods.
A hierarchical clustering analysis was then conducted on this final
dataset to group metabolites based on their postprandial kinetics (amap
and dendextend R packages, clustering by Spearman’s distance measure
and Ward linkage). Five clusters were chosen based on the visual differ-
ences in the postprandial responses.
Orthogonal projections to latent structures discriminant analysis
(OPLS-DA, SIMCA-P software v.14.0, Umetrics, Umeå, Sweden) was
conducted to differentiate milk from yogurt, or serum after milk intake
from serum after yogurt intake. The dataset was scaled through the use
of the unit variance method to make all metabolites equally important
and to limit the over-influence of metabolites with manyfold changes.
The incremental AUC was used for postprandial data (MESS R pack-
age). Quality of the models was evaluated by the goodness-of-fit pa-
rameter (R2Y) and the predictive ability parameter (Q2, calculated by
12-fold cross-validation). Subsequently, to rule out any random separa-
tion of the sample groups, permutation tests with 999 random permu-
tations were carried out (32). Finally, the most discriminatory metabo-
lites were selected based on variable importance in projection (VIP)
scores. Both VIPtot (VIP scores for the predictive and orthogonal com-
ponents) and VIPpred (VIP scores for the predictive component) were
calculated (33). VIPtot > 1 was used as the minimum threshold value
for variable selection. VIPpred, VIPtot, as well as the Jack-Knife 95%
confidence intervals (VIPtot_CI) are indicated in Supplemental Table 3.
In addition to the multivariate approach, a univariate analysis was per-
formed, as the 2 methods have been shown to be complementary (34).
A paired Wilcoxon’s signed rank test was conducted on each metabo-
lite to compare the products, the postprandial serum, and the fasting
serum. Multiple comparisons were adjusted by Benjamini Hochberg’s
correction (P= 0.05 as the threshold for significance). The Kolmogorov-
Smirnov test was used to compare the mass distributions of discriminat-
ing metabolites (R 3.1.2).
Results
A total of 2302 unique metabolites were detected in the test
products or serum and used for further statistical analysis.
Figure 2 summarizes the parts of the metabolome that are
shared between the different types of sample.
Products metabolome. A higher number of metabolites was
measured in yogurt compared with milk, in line with the ex-
pected release of new metabolites during fermentation. Sixteen
percent of the milk metabolome (73 metabolites) was no longer
detected in yogurt, whereas 24% of the yogurt metabolome
was not present in milk (122 new metabolites). Nevertheless,
395 metabolites remained present in both products, represent-
ing 84% and 76% of the milk and yogurt metabolome, respec-
tively. The multivariate analysis confirmed the clear difference
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FIGURE 2 Shared metabolites between milk, yogurt, and postpran-
dial serum of healthy men, assessed by LC-MS–based metabolomics.
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FIGURE 3 Differentiation of dairy products and serum samples of healthy men after milk or yogurt intake through the use of untargeted LC-MS
metabolomics. OPLS-DA scores plot derived from (A) milk and yogurt samples, (B) postprandial serum after milk and yogurt intake (800 g), and
(C) fasting serum after 2 wk of daily intake (400 g/d) of milk or yogurt. OPLS-DA, orthogonal projections to latent structures discriminant analysis;
Q2, predictive ability parameter; R2Y, goodness-of-fit parameter; t[1], OPLS-DA predictive component; to[1], OPLS-DA orthogonal component.
between the 2 product metabolomes (Figure 3A). The OPLS-
DA model showed goodness-of-fit and high prediction abil-
ity (R2Y = 0.98, Q2 = 0.98), both indicators being higher
than the corresponding values from the permutation test
(Supplemental Figure 2). Among the 590 metabolites measured
in milk and/or yogurt, 432 (73%) could discriminate milk from
yogurt (VIPtot > 1 or P < 0.05). Comparison of the mass dis-
tribution of the discriminatory metabolites (m/z, Figure 4A)
revealed that metabolites with higher concentrations in milk
(i.e., decreased during fermentation) had a significantly lower
mass distribution compared with metabolites with higher con-
centrations in yogurt (i.e., produced during fermentation) (one-
sided Kolmogorov-Smirnov test, P = 5.46 × 10−3).
Postprandial serum metabolome: general trends. A total
of 1785 metabolites were detected in serum. The nparLD anal-
ysis showed that approximately half of the serum metabolome
(51%, 906metabolites) showed a dynamic response to the acute
intake of milk and/or yogurt, 29% (524 metabolites) after the
intake of milk and yogurt, 13% (231 metabolites) after the in-
take of milk only, and 9% (151 metabolites) after the intake of
yogurt only. The remaining metabolites (49%, 879 metabolites)
did not display significant postprandial kinetics.
The 906 metabolites presenting a significant postprandial ki-
netic response were then used to build an OPLS-DA model to
differentiate postprandial serum after milk intake from post-
prandial serum after yogurt intake. The model was shown to be
reliable (R2Y = 0.97, Q2 = 0.74) with a clear separation be-
tween the 2 treatments (Figure 3B and Supplemental Figure 3).
Based on VIPtot scores and P values, 282 metabolites (31%)
were selected as discriminant, i.e., presenting a different post-
prandial response depending on whether milk or yogurt was
ingested (VIPtot > 1 or P < 0.05). Figure 5 shows the postpran-
dial kinetics of these 282 serum metabolites after the intake of
milk and yogurt. Further details regarding their retention times,
neutral masses, adducts, and identification suggestions are given
in Supplemental Table 3. Hierarchical clustering analysis could
distinguish 5 main groups of metabolites. Two hundred and
thirty-six metabolites increased postprandially (clusters 1, 2,
4, and 5), including 116 with a higher response after yogurt
intake (clusters 1, 2, and a few of cluster 4). A group of
46 features decreased postprandially (cluster 3), the decrease
of these metabolites being less pronounced after yogurt in-
take with a return to baseline concentrations after 6 h. The
Kolmogorov-Smirnov distribution test on mass distributions
showed that the metabolites having a higher response after yo-
gurt intake (clusters 1 and 2) had a significantly lower mass
distribution than the metabolites having a higher response af-
ter milk intake (clusters 4 and 5) (m/z, P = 4.41 × 10−6,
Figure 4B).
Fasting serum metabolomes after 2 wk of daily intake:
general trends. Of the 1785 metabolites detected in serum,
185 (10%) were changed in fasting samples assessed after the
2-wk daily intake of milk and/or yogurt (paired Wilcoxon’s
signed rank test, P < 0.05). The 185 metabolites were then
used to build an OPLS-DA model in order to differentiate fast-
ing serum assessed after 2 wk of daily intake of milk from
that assessed after 2 wk of daily intake of yogurt. The re-
sulting model could separate the 2 groups of samples with a
goodness-of-fit parameter R2Y = 0.97 and a predictive ability
parameter Q2 = 0.56, slightly over the recommended threshold
(Q2 > 0.50) (31) (Figure 3C and Supplemental Figure 4). As
expected, the differentiation of fasting serum was less marked
than that of the postprandial serum.
Based on VIPtot scores, 81 metabolites were selected as dis-
criminant for fasting serum samples (VIPtot > 1). Among them,
31 metabolites were also discriminant for postprandial serum
samples (VIPtot > 1, both postprandially and fasting); their dis-
tribution in the 5 postprandial kinetic clusters and their di-
rection of change under fasting conditions are indicated in
Figure 5. Interestingly, 29 had a postprandial behavior that
matched their concentration in fasting serum; i.e., when their
serum concentrations were higher postprandially after yogurt
intake, they remained higher in fasting serum after 2 wk of yo-
gurt intake, and similarly for milk intake. In total, 36% of the
changes observed in the fasting serum metabolome after 2 wk
of daily intake of dairy could already be observed during the
postprandial test.
Identification. Discriminatory metabolites were submitted to
a multistep identification procedure, including database search-
ing, collision-induced fragmentation, and the injection of
standards. The identities of 18 discriminant features were
confirmed with the injection of a standard and, if nec-
essary, additional fragmentation pattern analysis. Identified
discriminatory metabolites are listed in Table 1 with additional
information concerning their concentrations in the test prod-
ucts and serum. Among the identified features, GDL and its
hydrolyzed form, gluconic acid, were the most discriminatory
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FIGURE 4 Differentiation of the size distribution of metabolites in
dairy products and serum samples of healthy men after milk or yo-
gurt intake through the use of untargeted LC-MS metabolomics. (A)
Cumulative mass distribution of all milk metabolites, metabolites that
decreased during fermentation, or metabolites that were produced
during fermentation (OPLS-DA VIPtot > 1 or P < 0.05). (B) Cumu-
lative mass distribution of all serum metabolites, metabolites with
higher postprandial serum concentration after milk intake, or metabo-
lites with higher postprandial serum concentration after yogurt intake
(OPLS-DA VIPtot > 1 or P < 0.05). * P < 0.01, Kolmogorov-Smirnov
test between the 2 indicated distributions. OPLS-DA, orthogonal pro-
jections to latent structures discriminant analysis; VIPtot, variable im-
portance in projection for the predictive and orthogonal components.
metabolites of the postprandial response to dairy products
(Supplemental Figure 5A, cluster 4 in Figure 5). As explained,
GDL was purposely added to milk for acidification and texture
modification. GDL and gluconic acid were rapidly absorbed af-
ter milk ingestion with maximum concentrations being reached
by 3 h and remaining higher than baseline concentrations after
6 h. Interestingly, concentrations of both GDL and gluconic
acid remained higher in fasting serum after 2 wk of daily in-
take of acidified milk compared to yogurt intake (VIPtot = 1.12,
VIPtot_CI< 1 for both metabolites).OPLS-DAmodels were also
tested without GDL and gluconic acid since GDLwas purposely
added to the milk, but the outcomes remained unchanged.
A group of 7 metabolites were identified as free amino acids.
Their influence on the OPLS-DA model appeared to be limited
(VIPtot > 1, VIPtot_CI < 1, Supplemental Table 3); however,
all of these metabolites showed a postprandial increase, with
a higher response after yogurt intake (Table 1, Supplemental
Figure 5A–C). The essential amino acids that were identified
(threonine, lysine, and phenylalanine), as well as tyrosine that
is derived from phenylalanine, were grouped in cluster 2, with
a rapid increase (maximum serum concentration at 1 h) and a
return to baseline value after 4 h.On the other hand, asparagine
showed a slower increase (maximum serum concentration at
3 h) and returned to baseline at 6 h (cluster 4). Most of the
postprandial concentrations of the amino acids were in accor-
dance with their contents in the test products. This was the case
for lysine, phenylalanine, asparagine, and tyrosine, which were
present at higher concentrations in yogurt compared with milk.
The metabolite identified as taurine presented higher postpran-
dial concentrations after milk intake. A significant increase in
free tryptophan was observed in postprandial serum after milk
and yogurt intake (nparLD P = 2.26 × 10−7 and 5.08 × 10−12,
respectively).However, there was nomarked difference between
the 2 treatments (VIPtot = 0.34) despite the higher tryptophan
content in yogurt compared with milk (Table 1, Supplemental
Figure 5C).
Conversely, a clear difference was seen postprandially
for indole compounds that are products of tryptophan
metabolism. Indole-3-lactic acid (ILA), indole-3-acetaldehyde
(IAAld), indole-3-acetic acid (IAA), and 3-indole propionic acid
(IPA) were among the most discriminatory metabolites post-
prandially, although with very different kinetic behaviors (Sup-
plemental Figure 5E). ILA and IAAld clearly discriminated yo-
gurt intake from milk intake. The differences observed between
the products (higher concentration in yogurt) were also visible
in postprandial serum (rapid increase after yogurt intake). Con-
versely, IPA could not be detected in either milk or yogurt. A
significant postprandial increase was observed during the 6 h
after milk intake (nparLD P = 9.61 × 10−6), whereas no signif-
icant postprandial response could be observed after yogurt in-
take (nparLD P> 0.05). The postprandial difference for IPA be-
tween milk and yogurt intake (VIPtot = 1.47, VIPtot_CI< 1) was
also apparent in fasting serum (VIPtot = 1.32, VIPtot_CI < 1).
IAA showed a significant postprandial increase after milk intake
(nparLD P = 1.72 × 10−3) with a return to baseline after 6 h
whereas a continuous decrease from 60min to 6 h was observed
after yogurt intake (nparLD P = 6.12 × 10−9). IAA showed
some discrimination for postprandial serum (VIPtot = 1.62,
VIPtot_CI < 1) and was not discriminating for fasting serum
after daily intake of yogurt and milk.
Among the most discriminant identified features with a
significant response after milk or yogurt intake, 5 metabo-
lites were identified as BAs (Supplemental Figure 5C, D).
All the identified BAs presented a postprandial increase and
were classified in cluster 5 with maximum concentrations
between 60 and 180 min. In each case, the postprandial
increase was lower after yogurt intake (Table 1). This difference
was particularly marked for tauroursodeoxycholic acid and 3b-
hydroxy-5-cholenoic acid (VIPtot = 2.01 and 2.19, respectively,
VIPtot_CI> 1).However, this effect of yogurt intake appeared to
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FIGURE 5 Serum metabolites discriminant for the postprandial response after milk or yogurt intake in healthy men, clustered by postprandial
kinetics. Clustering by Spearman’s distance measure and Ward linkage. Five main clusters are identified. Metabolites with higher serum con-
centrations after milk intake or after yogurt intake are identified for the postprandial test (800 g intake, iAUC) and fasting after 2 wk of daily intake
(400 g/d). *OPLS-DA VIPtot > 1 or P < 0.05. A.U., arbitrary units; iAUC, incremental AUC; OPLS-DA, orthogonal projections to latent structures
discriminant analysis; VIPtot, variable importance in projection for the predictive and orthogonal components.
be transitory since no difference could be seen in fasting serum
after 2 wk of daily intake.
Discussion
Through the use of an untargeted LC-MS–based metabolomics
approach, our study has characterized the metabolic footprint
of fermentation, not only in the dairy metabolome but also in
the serum metabolome after acute or short-term (2-wk) intake
of milk and yogurt.
Products metabolome. Our comparative evaluation of milk
and yogurt has shown a complexification of the milk
metabolome during fermentation. There is little research that
describes the milk fermentation process with the use of untar-
geted metabolomics. Among the existing studies in this field,
free amino acids, peptides, and volatile compounds are the most
frequently reported metabolites that are released in yogurt (35,
36), cheese (37), and various fermented milks (38). Our study
indicates that globally,milk metabolites used by LAB during fer-
mentation have a smaller mass than metabolites subsequently
released in yogurt. This difference would reflect the presence
in yogurt of oligopeptides from caseins hydrolysis (higher con-
centrations of low molecular weight peptides, Supplemental
Table 2), of oligosaccharides (from bacterial exopolysaccha-
rides) (39), or of other complex metabolites constitutive of the
biomass (40).However, the results of such comparisons between
products highly depend on the analytical method used. In our
case, the removal of phospholipids and the use of the positive
ionization mode might have influenced these results.
Postprandial serum metabolome: general trends. We have
also shown that, despite milk and yogurt being similar in their
composition, and despite the generic effects of digestion and in-
testinal transport on the macronutrients present in these prod-
ucts, the acute ingestion of milk or yogurt resulted in 2 different
postprandial serum metabolic profiles, with 16% of the serum
metabolome responding differently. The effect of yogurt intake
on the serum metabolome was not limited to the exogenous
metabolites that were absorbed from the food but also included
changes relating to endogenous metabolic pathways, hence the
variety of kinetics profiles observed among the discriminatory
metabolites (Figure 5). It appeared that serum metabolites spe-
cific to yogurt intake (i.e., metabolites with a greater postpran-
dial increase after yogurt intake) had a significantly lower mass
compared with metabolites specific to milk intake. Such differ-
ences in mass distribution could be due to the presence in yo-
gurt of fermentation products derived from LAB activity, such
as volatile compounds (e.g., SCFAs) (35, 41), oligonucleotides
(42), or free amino acids, and also to the fact that yogurt com-
ponents of higher mass did not reach the circulation.
Amino acids. Native milk proteins have been described as
a good source of free amino acids with respect to plant-
derived proteins (43) and essential amino acids were shown to
be preferentially released during milk in vitro digestion (44).
856 Pimentel et al.
TA
B
LE
1
Id
en
tifi
ed
se
ru
m
m
et
ab
ol
ite
s
di
sc
rim
in
an
t
fo
r
th
e
po
st
pr
an
di
al
re
sp
on
se
af
te
r
m
ilk
or
yo
gu
rt
in
ta
ke
in
he
al
th
y
m
en
1
Re
te
nt
io
n
tim
e
(m
in
)_
Ad
du
ct
m
as
s
(D
a/
ch
ar
ge
)
M
ea
su
re
d
ne
ut
ra
l
m
as
s
(D
a)
Id
en
tifi
ca
tio
n
Pu
bC
he
m
CI
D
Ad
du
ct
s
Id
en
tifi
ca
tio
n
m
et
ho
d2
Pr
od
uc
tw
ith
th
e
hi
gh
es
t
co
nt
en
t
Pr
od
uc
tc
au
si
ng
th
e
hi
gh
es
t
po
st
pr
an
di
al
re
sp
on
se
Po
st
pr
an
di
al
ki
ne
tic
cl
us
te
r
Pr
od
uc
tc
au
si
ng
th
e
hi
gh
es
tf
as
tin
g
se
ru
m
co
nc
en
tra
tio
n
af
te
r2
w
k
of
da
ily
in
ta
ke
1.
11
_2
19
.0
47
0
19
6.
05
78
Gl
uc
on
ic
ac
id
10
,6
90
.+
H;
+N
a
1,
2,
4
M
ilk
*
M
ilk
*
4
M
ilk
*
1.
11
_1
79
.0
55
0
17
8.
04
78

-G
lu
co
no
la
ct
on
e
73
6
.+
H
1,
4
M
ilk
*
M
ilk
*
4
M
ilk
*
1.
16
_1
38
.0
52
8
11
5.
06
36
Pr
ol
in
e
14
5,
74
2
.+
H;
.+
N
a;
+2
N
a-
H;
.x
2+
H;
.x
2+
N
a
1,
4
M
ilk
*
Yo
gu
rt*
1
Yo
gu
rt
0.
92
_1
47
.1
12
3
14
6.
10
51
Ly
si
ne
59
62
.+
H;
.+
N
a;
.+
2N
a-
H;
.+
H-
H2
O
1,
4
Yo
gu
rt*
Yo
gu
rt*
2
Yo
gu
rt
1.
06
_1
64
.0
29
0
11
9.
05
78
Th
re
on
in
e
62
88
.+
H;
.+
2N
a-
H;
.+
N
a
1,
4
M
ilk
Yo
gu
rt*
2
Yo
gu
rt
3.
43
_1
66
.0
86
1
16
5.
07
89
Ph
en
yl
al
an
in
e
61
40
.+
H;
.x
2+
H
1,
4
Yo
gu
rt*
Yo
gu
rt*
2
M
ilk
1.
28
_1
74
.0
86
8
13
2.
05
34
As
pa
ra
gi
ne
62
67
.+
AC
N
+H
;.
+N
a;
.+
H-
H2
O
1,
4
nd
Yo
gu
rt*
4
M
ilk
2.
31
_1
82
.0
80
7
18
1.
07
34
Ty
ro
si
ne
60
57
.+
H;
.+
N
a
1,
4
Yo
gu
rt*
Yo
gu
rt*
2
M
ilk
4.
23
_2
05
.0
97
2
20
4.
08
99
Tr
yp
to
ph
an
63
05
.+
H;
.+
N
a
1,
2,
3,
4
Yo
gu
rt*
Yo
gu
rt
—
M
ilk
1.
07
_1
98
.0
84
6
17
5.
09
54
Ci
tru
lli
ne
97
50
.+
H;
.+
N
a;
+2
N
a-
H
1,
4
nd
Yo
gu
rt*
1
Yo
gu
rt
1.
07
_1
26
.0
21
4
12
5.
01
42
Ta
ur
in
e
11
23
.+
H;
+2
N
a-
H;
.+
N
a;
.+
H-
H2
O
1,
4
Yo
gu
rt
M
ilk
*
4
M
ilk
6.
04
_2
06
.0
80
7
20
5.
07
35
In
do
le
-3
-la
ct
ic
ac
id
92
,9
04
.+
H;
.+
N
a
1,
2,
3,
4
Yo
gu
rt*
Yo
gu
rt*
1
Yo
gu
rt
6.
04
_1
60
.0
75
3
15
9.
06
80
In
do
le
-3
-a
ce
ta
ld
eh
yd
e
80
0
.+
H
1,
2
Yo
gu
rt*
Yo
gu
rt*
1
Yo
gu
rt
6.
67
_1
76
.0
70
1
17
5.
06
29
In
do
le
-3
-a
ce
tic
ac
id
80
2
.+
H;
.+
N
a
1,
2,
3,
4
nd
M
ilk
*
5
M
ilk
7.
26
_1
90
.0
85
8
18
9.
07
85
3-
In
do
le
pr
op
io
ni
c
ac
id
37
44
.+
H;
.+
N
a;
.+
H+
H2
O
1,
2,
4
nd
M
ilk
*
4
M
ilk
*
9.
91
_3
75
.2
88
7
37
4.
28
14
3b
-H
yd
ro
xy
-5
-c
ho
le
no
ic
ac
id
92
,9
97
.+
H;
.+
H-
H2
O;
.+
H-
2H
2O
1,
2,
3,
4
nd
M
ilk
*
5
Yo
gu
rt
10
.1
0_
43
4.
32
56
39
2.
29
20
(c
he
no
)D
eo
xy
ch
ol
ic
ac
id
22
2,
52
8
.+
H;
.+
N
a;
.+
N
H4
;.
+H
-H
2O
;
.+
H-
2H
2O
;.
x2
+H
1,
2,
3,
4
nd
M
ilk
*
5
Yo
gu
rt
8.
46
_4
50
.3
20
5
44
9.
31
32
Gl
yc
ou
rs
od
eo
xy
ch
ol
ic
ac
id
12
,3
10
,2
88
.+
H;
.+
N
H4
;.
+N
a;
.x
2+
H;
.x
2+
N
a;
.x
2+
N
H4
;.
+H
-H
2O
;
.+
H-
2H
2O
1,
2
nd
M
ilk
*
5
M
ilk
7.
40
_4
83
.3
41
5
46
5.
30
77
Gl
yc
oc
ho
lic
ac
id
10
,1
40
.+
H;
.+
N
H4
;.
+N
a;
.+
H-
H2
O;
.+
H-
2H
2O
1,
2,
4
nd
M
ilk
*
5
Yo
gu
rt
9.
51
_5
00
.3
02
8
49
9.
29
56
Ta
ur
ou
rs
od
eo
xy
ch
ol
ic
ac
id
9,
84
8,
81
8
.+
H;
.+
H-
H2
O;
.+
H-
2H
2O
1,
2,
3,
4
nd
M
ilk
*
5
M
ilk
1
*O
P
LS
-D
A
V
IP
to
t
sc
or
e
>
1
or
P
<
0.
05
.C
ID
,c
om
po
un
d
id
en
tifi
er
;n
d,
no
td
et
ec
te
d;
O
P
LS
-D
A
,o
rt
ho
go
na
lp
ro
je
ct
io
ns
to
la
te
nt
st
ru
ct
ur
es
di
sc
rim
in
an
ta
na
ly
si
s;
V
IP
to
t,
va
ria
bl
e
im
po
rt
an
ce
in
pr
oj
ec
tio
n
fo
rt
he
pr
ed
ic
tiv
e
an
d
or
th
og
on
al
co
m
po
ne
nt
s.
2
Id
en
tifi
ca
tio
n
m
et
ho
ds
:1
,m
as
s
da
ta
ba
se
;2
,t
he
or
et
ic
al
fr
ag
m
en
ta
tio
n;
3,
fr
ag
m
en
t
da
ta
ba
se
;4
,s
ta
nd
ar
d
in
je
ct
io
n.
Metabolic footprinting of fermented milk consumption 857
Milk-derived free amino acids have been discussed in the con-
text of postprandial skeletal muscle protein synthesis, after re-
sistance exercise (45) and in elderly populations that exhibit low
skeletal muscle mass (sarcopenia) (46). In this study, higher post-
prandial concentrations of 7 free amino acids were observed af-
ter yogurt intake with respect to milk intake, 3 being essential
(phenylalanine, threonine, and lysine). These differences could
be related to the prior hydrolysis of milk proteins during fer-
mentation (Supplemental Table 2), with similar trends observed
in postprandial urine after cheese intake compared with milk
intake (25). Prior fermentation might therefore be considered
as a means to increase circulating free amino acids after dairy
intake. However, as suggested by the kinetics profiles (Supple-
mental Figure 5A–C), the differences in postprandial free amino
acids between milk and yogurt intake appeared to be rather lim-
ited in intensity and in time (returning to baseline values after
4–6 h), which might explain why they were no longer discrimi-
nant in fasting serum after 2 wk of the daily interventions.
Indole derivatives. Indole compounds are known products of
microbial metabolism of tryptophan via the “indole pathway”.
In the present study, probably owing to the proteolytic activity
of LAB during fermentation, we report higher concentrations
of free tryptophan in yogurt compared with milk. The subse-
quent use of free tryptophan by LAB during fermentation (47)
explains the higher concentrations of ILA and IAAld in yogurt,
resulting in higher postprandial serum concentrations after yo-
gurt intake. In humans, ILA being an end-product of the trypto-
phan metabolic pathway (48), it is likely to accumulate in serum
postprandially. In accordance with our observation, an increase
in postprandial ILA has been reported in plasma after the inges-
tion of different whey protein fractions, the ILA concentrations
positively correlating with the tryptophan content in the differ-
ent fractions (49).
The use of dietary free tryptophan by the microbiota and
the subsequent release of indole derivatives reaching the blood
could also contribute to the presence of indole derivatives in
postprandial serum. Such mechanisms have only been described
in rodents to date (50, 51). Under high-tryptophan conditions,
as is the case in our study after yogurt intake, a 2-fold increase in
tryptophanase activity has been reported in murine microbiota,
tryptophanase being a key enzyme in the indole pathway (52).
Moreover, as described by Zelante et al. (51), in unrestricted
tryptophan conditions intestinal lactobacilli favor tryptophan
as a source of energy over carbohydrates. It is then likely that
the excess in tryptophan provided by the yogurt is directly me-
tabolized by the intestinal microbiota, especially via the indole
pathway (51, 53).
As IPA and IAA were not detected in either milk or yogurt,
their presence in postprandial serum could be of intestinal mi-
crobiota origin. IPA has been reported as being produced in the
intestine specifically by Clostridium sporogenes (50, 54). Fur-
thermore, a similar increase in IPA during the late postprandial
phase has been previously described after the intake of 500 mL
dairy shake (55).The lower IPA and IAA concentrations reached
in blood after yogurt intake may appear to be contradictory
considering the higher tryptophan content in yogurt. However,
in a human intervention study investigating protein intake and
tryptophan metabolites, no correlation could be observed be-
tween plasma tryptophan and plasma IAA, and in mice plasma
IAA was lowered after a high-protein diet (56). The interactions
of the microbiota with foods make any mechanistic explana-
tion even more complex. For example, yogurt bacterial species
have been shown to inhibit C. sporogenes growth (57) and its
adhesion to intestinal epithelial cells (58), which could result in
a lower intestinal production of IPA. Other mechanisms, such
as the binding to the aryl hydrocarbon receptor (AhR) (59) or
enzymatic degradation in the circulation, may also contribute
to the postprandial responses observed here.
Indole derivatives have recently been investigated for their
role on the epithelial barrier function and gut inflammatory
homeostasis via their activation of the AhR signaling pathway,
IAA and IAAld being ligands for this receptor (51, 54, 59, 60).
Strikingly, the whole blood transcriptomic analysis of our post-
prandial samples independently identified the gene coding for
AhR among the top genes showing significant change after yo-
gurt intake (61).
BAs. Primary BAs are synthesized in the liver and are conju-
gated to glycine and taurine before excretion in the duodenum.
The influence of the intestinal microbiota on the pool size and
composition of BAs is well documented (62) and mainly relies
on the expression of bile salt hydrolase (BSH) by colonic bac-
teria, hydrolyzed BAs being less efficiently reabsorbed into the
enterohepatic recirculation (63–66). Consequently, dietary pro-
biotics have been tested to modulate metabolism of BAs, with
the aim of influencing the host metabolism including cholesterol
and TG pathways (65). As a result, BSH activity has been pro-
posed as a requirement for probiotic organisms (67). The pres-
ence of the BSH gene in the genome of LGG (LRHM_0484) and
the known BSH activity of S. thermophilus and L. delbrueckii
ssp. bulgaricus (68) could explain the lower postprandial con-
centrations observed here after yogurt intake. In addition, all 3
yogurt strains have the capacity to survive in the gastrointesti-
nal tract after ingestion (22, 69). Furthermore, it is worth noting
that taurine, which is used in the liver for de novo BA synthe-
sis, tends to have a lower postprandial response after yogurt in-
take compared with milk intake. However, this change in serum
BAs appeared to be transitory as no difference was observed in
fasting serum after daily intake. In contrast, other intervention
studies have reported an increase in circulating BA (conjugated
or unconjugated) after chronic intake of the BSH-active Lac-
tobacillus reuteri (70, 71). These studies do however differ in
important aspects of study design, including mode of adminis-
tration (capsules), choice of probiotic strains, as well as the du-
ration of the studies (up to 6 wk). Interestingly, our group of dis-
criminant BAs included conjugated (glycoursodeoxycholic acid)
and unconjugated [(cheno)deoxycholic acid] BAs, as well as a
primary BA synthesized by the liver (3b-hydroxy-5-cholenoic
acid) and a secondary BA of microbial origin (glycocholic acid),
reflecting the complexity of the mechanisms behind the regula-
tion of BA metabolism.
Fasting metabolome after 2 wk of daily intake: general
trends. Interestingly, more than a third of the changes detected
in fasting assessments after 2 wk were already visible postpran-
dially. Although most of the identities of these metabolites are
not yet confirmed, these results nevertheless give an estimation
of the ability of acute postprandial studies to predict changes
that are likely to occur after chronic intake. The postprandial
phase is generally less frequently studied in nutritional inter-
ventions, which tend to focus on fasting measurements after
semichronic or chronic intake to identify long-term effects (16,
19, 21, 72). However, considering the typical meal frequency in
Western countries, most individuals are in a postprandial state
during the day and, therefore, looking at the postprandial phase
may also help to identify dietary biomarkers as well as to under-
stand the mechanisms underpinning long-term effects of diet.
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Conclusion. To conclude, we firstly observed that milk and yo-
gurt still share most of their metabolites. Nonetheless, fermen-
tation left an identifiable footprint on the product metabolome,
and more importantly, on the serum metabolome, postprandi-
ally after acute intake, as well as fasting after short-term daily
intake. The postprandial modulation of circulating amino acids,
indole derivatives, and BAs suggests that the metabolic footprint
of fermented dairy intake does not only consist in the absorp-
tion of metabolites from the product, but also in the regulation
of the endogenous metabolic activity, notably that of the intesti-
nal microbiota. Such metabolites could be used as targets in ob-
servational studies to identify potential benefits of fermented
dairy products on cholesterol and TG concentrations through
the modulation of BAs, or on inflammatory status through the
AhR signaling pathway. Moreover, assessing the expression of
genes involved in these pathways could identify the molecular
targets modulated by these metabolites as well as clarify the
mechanisms underlying such effects. Finally, compounds like in-
dole derivatives might be considered as biomarkers of fermented
dairy intake in observational studies, with the limitation that
other nondairy fermented food can also be a source of such
metabolites [kimchi, sauerkraut, or pickles (73)].
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